Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis

Pharmacotherapy

Volumn 17, Issue 2, 1997, Pages 263-270

  Jones, Kristen M ^a   Liao, Edward ^a   Hohneker, Kathy ^a   Turpin, Stephen ^a   Henry, Marianna M ^a   Selinger, Krzysztof ^a   Hsyu, Poe Hirr ^a   Boucher, Richard C ^a   Knowles, Michael R ^a   Dukes, George E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; AUTOSOMAL RECESSIVE INHERITANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LUNG DISEASE; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AEROSOLS; AMILORIDE; CHILD; CROSS-OVER STUDIES; CYSTIC FIBROSIS; DIURETICS; HUMANS;

EID: 0030901674     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Boat TF, Welsh MJ, Beaudet AL. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. The metabolic basis of inherited disease. New York: McGraw-Hill, 1989:2649-80.
2. Knowles M, Gatzy J, Boucher R. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med 1981;305:1489-95.
3. App EM, King M, Helfesieder R, Kohler D, Mattys H. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. Am Rev Respir Dis 1990;141:605-12.
4. Knowles M, Murray G, Shallal J, Askin F, Ranga V. Bioelectric properties and ion flow across excised human bronchi. J Appl Physiol 1984;56:868-77.
5. Tomkiewicz R, App E, Zayas J, et al. Amiloride inhalation therapy in cystic fibrosis. Influence on ion content, hydration, and rheology of sputum. Am Rev Respir Dis 1993;148: 1002-7.
6. Liao E, Wood R, Blair K, et al. Pharmacokinetics of aerosolized amiloride in pediatric patients with mild to moderate cystic fibrosis [abstr]. Pharmacotherapy 1993; 13(3):292-3.
7. Knowles M, Church N, Waltner W, et al. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990;322:1189-94.
8. Smith A, Smith R. Kinetics and bioavailability of two formulations of amiloride in man. Br J Pharmacokinet 1973;48:646-9.
9. Spahn H, Reuter K, Mutschler E, Gerok W, Knauf H. Pharmacokinetics of amiloride in renal and hepatic disease. Eur J Clin Pharmacol 1987;33:398-493.
10. Weiss P, Hersey R, Dujovne C, Bianchine J. The metabolism of amiloride hydrochloride in man. Clin Pharmacol Ther 1969;10:401-6.
11. Sabanathan K, Castleden C, Adam H, Ryan J, Fitzsimons T. A comparative study of the pharmacokinetics and pharmacodynamics of atenolol, hydrochlorothiazide, and amiloride in normal young and elderly subjects and elderly hypertensive patients. Eur J Clin Pharmacol 1987;32:53-60.
12. Sly P, LeSouef P. Inhaled therapy in paediatrics. J Paediatr Child Health 1991;27:7-10.
13. Newman SP. Therapeutic aerosol deposition in man. In: Moren F, Dolovich MB, Newhouse MT, Newman SP, eds. Aerosols in medicine. Principles, diagnosis and therapy, 2nd ed. Amsterdam: Elsevier, 1993:375-6.
14. Borgstrom L, Nilsson M. A method for determination of the absolute pulmonary bioavailability of inhaled drugs: terbutaline. Pharmaceut Res 1990;7(10):1068-70.
15. Hollie MC, Malone RA, Skufca RM, Nelson HS. Extreme variability in aerosol output of the DeVilbiss 646 jet nebulizer. Chest 1991;100:1339-44.